Pharvaris (NASDAQ: PHVS) presented clinical data on deucrictibant at the European Academy of Allergy and Clinical Immunology Annual Congress held June 12-15, 2026, in Istanbul, Turkey.

The company reported results from the RAPIDe-3 Phase 3 study evaluating deucrictibant immediate-release capsule (20 mg) for on-demand treatment of hereditary angioedema (HAE) attacks in participants 12 years and older. The study showed a median time to onset of symptom relief of 1.28 hours with deucrictibant versus over 12 hours with placebo. Complete resolution of attack symptoms occurred at a median of 11.95 hours with deucrictibant compared to over 48 hours with placebo.

In the study, 83.0% of deucrictibant-treated attacks required only a single capsule, and 93.2% did not need conventional rescue medication. The treatment was well tolerated with no treatment-related serious adverse events and no participants discontinuing due to treatment-emergent adverse events.

RAPIDe-3 represented the first study to assess End of Progression as a prespecified endpoint, defined as the earliest timepoint at which symptoms stop worsening. Deucrictibant achieved a median time to End of Progression of 17.47 minutes compared to 228.67 minutes with placebo.

The company also presented final data from the CHAPTER-1 open-label extension study investigating oral deucrictibant for prophylaxis. Participants were treated for up to approximately 34 months, showing sustained efficacy and favorable long-term safety. Attack frequency was reduced by approximately 92% from baseline, with about half of participants remaining attack-free during the extension period.

An integrated cardiovascular safety analysis across deucrictibant clinical studies included approximately 570 unique participants. The analysis showed no evidence of QT prolongation or clinically meaningful cardiac risks, with stable hemodynamic parameters and no clinically meaningful ECG changes observed.

Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsule as an on-demand HAE treatment, with a global Phase 3 study (CHAPTER-3) of the extended-release tablet for HAE prevention ongoing.